Type of study in modified release formu­lation EMEA [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2014-11-27 13:53 (3875 d 08:49 ago) – Posting: # 13930
Views: 15,624

❝ The guideline allows widening for Ctau,ss as for highly variable drugs. Did you go for that in the protocol?


Ok thanks for the reply. But I think for applying widening criteria we need to show CV>30% for reference product and the study should be reference replicate (3way or 4way).
Can we use Pre-dose concentration and Ctau of steady state to show variability?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,687 registered users;
96 visitors (0 registered, 96 guests [including 11 identified bots]).
Forum time: 23:42 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5